Skip to main content
. 2020 Aug 29;12(9):825. doi: 10.3390/pharmaceutics12090825

Table 2.

Characterization of heparin samples that combine different chemical modifications. Shadowed in gray are the formulations selected for in vivo assays.

Sample Mw (Da) SO3/Disaccharide IC50 (µg/mL ± SD) IC90 (µg/mL ± SD) aPTT (IU/mg) In Vitro Toxicity 1 (% ± SD) Hemolysis 1 (% ± SD)
MMWH_1 10,497 n.d. 22.7 ± 2.4 178.1 ± 28.4 110 1.1 ± 3.4 0.1 ± 0.2
MMWH_2 11,000 1.9 33.7 ± 21.8 374.8 ± 189.3 130 0.0 ± 6.0 0.5 ± 0.2
2-O-desulfated MMWH_1 8771 1.6 80.7 ± 5.0 270.3 ± 42.5 38 10.0 ± 3.0 0.3 ± 0.4
2-O-desulfated MMWH_2 8776 1.5 91.9 ± 9.0 351.9 ± 43.4 23 0.0 ± 2.3 2.0 ± 2.0
2-O-desulfated MMWH_3 10,198 1.5 59.1 ± 16.5 487.9 ± 161.3 53 17.9 ± 2.1 0.5 ± 0.2
2-O-desulfated MMWH_4 11,190 1.4 68.0 ± 14.5 404.8 ± 119.4 33 7.5 ± 1.8 0.0 ± 0.0
2-O-desulfated glycol-split MMWH_1 7388 1.8 79.6 ± 5.4 893.1 ± 321.0 6 7.3 ± 4.5 0.4 ± 0.1
2-O-desulfated glycol-split MMWH_2 7037 1.5 84.2 ± 13.4 303.4 ± 46.2 5 3.6 ± 5.4 0.0 ± 0.0
ULMWH 4270 2.2 49.3 ± 6.0 236.3 ± 54.9 6 6.8 ± 9.2 0.2 ± 0.1
2-O-desulfated ULMWH_1 4150 1.6 140.9 ± 15.9 322.5 ± 27.5 ud. 20.0 ± 16.7 0.0 ± 0.0
2-O-desulfated ULMWH_2 4450 1.4 129.2 ± 13.1 262.5 ± 16.1 ud. 37.0 ± 9.9 0.2 ± 0.0
2-O-desulfated glycol-split ULMWH_1 4024 1.7 104.4 ± 6.0 192.4 ± 16.2 ud. 2.5 ± 2.3 0.0 ± 0.2
2-O-desulfated glycol-split ULMWH_2 3800 1.6 130.3 ± 15.5 200.5 ± 111.6 ud. 11.5 ± 8.0 0.0 ± 0.1
UH, commercial 13,000 1.9–2.0 9.4 ± 4.4 135.5 ± 12.8 197 0.0 ± 6.0 0.0 ± 0.0

1 Reported in vitro toxicity in human umbilical vein endothelial cell (HUVEC) culture (% of cell death) and hemolysis data (% of lysed RBCs) have been calculated with 2 mg heparin/mL. The numbers after two compounds with the same name indicate that those samples are replicates, made in order to check the reproducibility of the procedure and tested separately to corroborate if there were any differences in antimalarial or anticoagulant activity. n.d.: not determined, ud.: undetected.